A chemifluorescent immunoassay for the determination of marinobufagenin in body fluids

Journal of Immunoassay and Immunochemistry

Volumn 32, Issue 1, 2011, Pages 31-46

  Abi Ghanem, Daad ^a   Lai, Xinzhong ^a   Berghman, Luc R ^a,b   Horvat, Darijana ^a   Li, Jing ^a   Romo, Daniel ^a   Uddin, Mohammad N ^a   Kamano, Yoshiaki ^c   Nogawa, Toshihiko ^c   Xu, Jun Ping ^c   Pettit, George R ^c   Puschett, Jules B ^a,d  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d Scott White Memorial Hospital and Clinic   (United States)

Author keywords

bufodienolides; cardiac glycosides; diagnostic; hypertension; immunoassay; marinobufagenin

Indexed keywords

BOVINE SERUM ALBUMIN; BUFALIN; BUFOGENIN; CINOBUFOTALIN; DIGOXIGENIN; DIGOXIN; MARINOBUFAGENIN; OUABAIN; POLYCLONAL ANTIBODY; PROSCILLARIDIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BODY FLUID; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE TEST; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; URINALYSIS;

ANIMALS; BUFANOLIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RABBITS; RATS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN, BOVINE;

EID: 79251471785     PISSN: 15321819     EISSN: 15324230     Source Type: Journal    
DOI: 10.1080/15321819.2010.538107     Document Type: Article

References (34)

1. Schoner, W. Endogenous Cardiac Glycosides, a New Class of Steroid Hormones. Eur. J. Biochem. 2002, 269, 2440-2448.
2. Luojun, K. ; Ke, Z. National Commission of Chinese Pharmacopoeia, Pharmacopoeia of Peoples Republic of China; Chemical Industry Press: Beijing, 2005.
3. Puschett, J. B. ; Agunanne, E. ; Uddin, M. N. Emerging Role of the Bufadienolides in Cardiovascular and Kidney Diseases. Am. J. Kidney Dis. 56, 359-370.
4. Pridjian, G. ; Puschett, J. B. Preeclampsia. Part 1: Clinical and Pathophysiologic Considerations. Obstet. Gynecol. Surv. 2002, 57, 598-618.
5. Vu, H. V. ; Ianosi-Irimie, M. R. ; Pridjian, C. A. ; Whitbred, J. M. ; Durst, J. M. ; Bagrov, A. Y. ; Fedorova, O. V. ; Pridjian, G. ; Puschett, J. B. Involvement of Marinobufagenin in a Rat Model of Human Preeclampsia. Am. J. Nephrol. 2005, 25, 520-528.
6. Fridman, A. I. ; Matveev, S. A. ; Agalakova, N. I. ; Fedorova, O. V. ; Lakatta, E. G. ; Bagrov, A. Y. Marinobufagenin, an Endogenous Ligand of Alpha-1 Sodium Pump, is a Marker of Congestive Heart Failure Severity. J. Hypertens. 2002, 20, 1189-1194.
7. Vu, H. ; Ianosi-Irimie, M. ; Danchuk, S. ; Rabon, E. ; Nogawa, T. ; Kamano, Y. ; Pettit, G. R. ; Wiese, T. ; Puschett, J. B. Resibufogenin Corrects Hypertension in a Rat Model of Human Preeclampsia. Exp. Biol. Med. 2006, 231, 215-220.
8. Gonick, H. C. ; Ding, Y. ; Vaziri, N. D. ; Bagrov, A. Y. ; Fedorova, O. V. Simultaneous Measurement of Marinobufagenin, Ouabain, and Hypertension-Associated Protein in Various Disease States. Clin. Exp. Hypertens. 1998, 20, 617-627.
9. Lopatin, D. A. ; Ailamazian, E. K. ; Dmitrieva, R. I. ; Shpen, V. M. ; Fedorova, O. V. ; Doris, P. A. ; Bagrov, A. Y. Circulating Bufodienolide and Cardenolide Sodium Pump Inhibitors in Preeclampsia. J. Hypertens. 1999, 17, 1179-1187.
10. Averina, I. V. ; Tapilskaya, N. I. ; Reznik, V. A. ; Frolova, E. V. ; Fedorova, O. V. ; Lakatta, E. G. ; Bagrov, A. Y. Endogenous Na=K-ATPase Inhibitors in Patients with Preeclampsia. Cell. Mol. Biol. 2006, 52, 19-23.
11. Bagrov, A. Y. ; Agalakova, N. I. ; Kashkin, V. A. ; Fedorova, O. V. Endogenous Cardiotonic Steroids and Differential Patterns of Sodium Pump Inhibition in NaCl-Loaded Salt-Sensitive and Normotensive Rats. Am. J. Hypertens. 2009, 22, 559-563.
12. Ma, X. C. ; Zhang, B. J. ; Xin, X. L. ; Huang, S. S. ; Deng, S. ; Zhang, H. L. ; Shu, X. H. ; Diao, Y. P. ; Cui, J. Simultaneous Quantification of Seven Major Bufadienolides in Three Traditional Chinese Medicinal Preparations of Chansu by HPLC-DAD. Nat. Prod. Commun. 2009, 4, 179-184.
13. Chen, K. K. , Kovarikova, A. Pharmacology and Toxicology of Toad Venom. J. Pharm. Sci. 1967, 56, 1535-1541.
14. Liang, Y. ; Liu, A. H. ; Qin, S. ; Sun, J. H. ; Yang, M. ; Li, P. ; Guo, D. A. Simultaneous Determination and Pharmacokinetics of Five Bufadienolides in Rat Plasma after Oral Administration of Chansu Extract by SPE-HPLC Method. J. Pharm. Biomed. Anal. 2008, 46, 442-448.
15. Shimada, K. ; Miyashiro, Y. ; Nishio, T. Characterization of In Vitro Metabolites of Toad Venom Using High-Performance Liquid Chromatography and Liquid Chromatography-Mass Spectrometry. Biomed. Chromatogr. 2006, 20, 1321-1327.
16. Fedorova, O. V. ; Simbirtsev, A. S. ; Kolodkin, N. I. ; Kotov, A. Y. ; Agalakova, N. I. ; Kashkin, V. A. ; Tapilskaya, N. I. ; Bzhelyansky, A. ; Reznik, V. A. ; Frolova, E. V. ; Nikitina, E. R. ; Budny, G. V. ; Longo, D. L. ; Lakatta, E. G. ; Bagrov, A. Y. Monoclonal Antibody to an Endogenous Bufadienolide, Marinobufagenin, Reverses Preeclampsia-Induced Na=K-ATPase Inhibition and Lowers Blood Pressure in NaCl-Sensitive Hypertension. J. Hypertens. 2008, 26, 2414-2425.
17. Kamano, Y. ; Nogawa, T. ; Kotake, A. ; Tozawa, M. ; Pettit, G. R. Separation of Toad Poison Bufadienolides by Hydrophobic Gel. J. Liq. Chromatogr. Related Technol. 1999, 22, 2455-2465.
18. Li, F. ; Yang, R. ; Weng, Y. ; Tang, X. Preparation and Evaluation of Lyophilized Liposome- Encapsulated Bufadienolides. Drug Dev. Indust. Pharm. 2009, 35, 1048-1058.
19. Nogawa, T. ; Kamano, Y. ; Yamashita, A. ; Pettit, G. R. Isolation and Structure of Five New Cancer Cell Growth Inhibitory Bufadienolides from the Chinese Traditional Drug Ch'an Su. J. Nat. Prod. 2001, 64, 1148-1152.
20. Inoue, M. ; Kamano, Y. ; Pettit, G. R. ; Smith, C. R. Separation of Bufotalin and Cinobufotalin by Preparative Liquid Chromatography. J. Liq. Chrom. 1987, 10, 2453-2460.
21. Pettit, G. R. ; Kamano, Y. Bufadienolides. 28. Marinobufotoxin. J. Org. Chem. 1974, 39, 3003-3006.
22. Kuojun, K. ; Ke, Z. National Commission of Chinese Pharmacopoeia, Pharmacopoeia of Peoples Republic of China; Chemical Industry Press: Beijing, 2005.
23. Brown, P. ; Kamano, Y. ; Pettit, G. R. High Resolution Mass Spectrometry. Bufadienolides-II. Org. Mass Spectrom. 1972, 6, 613-646.
24. Lipshutz, B. H. ; Pollart, D. ; Monforte, J. ; Kotsuki, H. Pd(II)-Catalyzed Acetal=Ketal Hydrolysis= Exchange Reactions. Tetrahedron Lett. 1985, 26, 705-708.
25. Schoner, W. ; Scheiner-Bobis, G. Endogenous and Exogenous Cardiac Glycosides: Their Roles in Hypertension, Salt Metabolism, and Cell Growth. Am. J. Physiol. Cell. Physiol. 2007, 293, C509- 0536.
26. Kennedy, D. J. ; Vetteth, S. ; Periyasamy, S. M. ; Kanj, M. ; Fedorova, L. ; Khouri, S. ; Kahaleh, M. B. ; Xie, Z. ; Malhotra, D. ; Kolodkin, N. I. ; Lakatta, E. G. ; Fedorova, O. V. ; Bagrov, A. Y. ; Shapiro, J. I. Central Role for the Cardiotonic Steroid Marinobufagenin in the Pathogenesis of Experimental Uremic Cardiomyopathy. Hypertension 2006, 47, 488-495.
27. Elkareh, J. ; Kennedy, D. J. ; Yashaswi, B. ; Vetteth, S. ; Shidyak, A. ; Kim, E. G. ; Smaili, S. ; Periyasamy, S. M. ; Hariri, I. M. ; Fedorova, L. ; Liu, J. ; Wu, L. ; Kahaleh, M. B. ; Xie, Z. ; Malhotra, D. ; Fedorova, O. V. ; Kashkin, V. A. ; Bagrov, A. Y. ; Shapiro, J. I. Marinobufagenin Stimulates Fibroblast Collagen Production and Causes Fibrosis in Experimental Uremic Cardiomyopathy. Hypertension 2007, 49, 215-224.
28. Fedorova, L. V. ; Raju, V. ; El-Okdi, N. ; Shidyak, A. ; Kennedy, D. J. ; Vetteth, S. ; Giovannucci, D. R. ; Bagrov, A. Y. ; Fedorova, O. V. ; Shapiro, J. I. ; Malhotra, D. The Cardiotonic Steroid Hormone Marinobufagenin Induces Renal Fibrosis: Implication of Epithelial-to-Mesenchymal Transition. Am. J. Physiol. Renal. Physiol. 2009, 296, F922-F934.
29. Uddin, M. N. ; McLean, L. B. ; Hunter, F. A. ; Horvat, D. ; Severson, J. ; Tharakan, B. ; Childs, E. W. ; Puschett, J. B. Vascular Leak in a Rat Model of Preeclampsia. Am. J. Nephrol. 2009, 30, 26-33.
30. Uddin, M. N. ; Horvat, D. ; Childs, E. W. ; Puschett, J. B. Marinobufagenin Causes Endothelial Cell Monolayer Hyperpermeability by Altering Apoptotic Signaling. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296, R1726-R1734.
31. Hosoda, H. ; Sakai, Y. ; Yoshida, H. ; Nambara, T. Enzyme Labeling of Steroids by the Activated Ester Method. Chem. Pharm. Bull. 1979, 27, 2147-2150.
32. Yoshika, M. ; Komiyama, Y. ; Konishi, M. ; Akizawa, T. ; Kobayashi, T. ; Date, M. ; Kobatake, S. ; Masuda, M. ; Masaki, H. ; Takahashi, H. Novel Digitalis-Like Factor, Marinobufotoxin, Isolated from Cultured Y-1 Cells, and Its Hypertensive Effect in Rats. Hypertension 2007, 49, 209-214.
33. Elkareh, J. ; Periyasamy, S. M. ; Shidyak, A. ; Vetteth, S. ; Schroeder, J. ; Raju, V. ; Hariri, I. M. ; El-Okdi, N. ; Gupta, S. ; Fedorova, L. ; Liu, J. ; Fedorova, O. V. ; Kahaleh, M. B. ; Xie, Z. ; Malhotra, D. ; Watson, D. K. ; Bagrov, A. Y. ; Shapiro, J. I. Marinobufagenin Induces Increases in Procollagen Expression in a Process Involving Protein Kinase C and Fli-1: Implications for Uremic Cardiomyopathy. Am. J. Physiol. Renal Physiol. 2009, 296, F1219-F1226.
34. Horvat, D. ; Severson, J. ; Uddin, M. N. ; Mitchell, B. ; Puschett, J. B. Resibufogenin Prevents the Manifestations of Preeclampsia in an Animal Model of the Syndrome. Hypertens. Pregnancy 2010, 29, 1-9.